Fresenius Medical Care AG & Co KGaA (Fresenius Medical Care) is a renal therapy company which provides dialysis services and products and equipment for the treatment of end-stage renal disease (ESRD). It develops and manufactures a comprehensive range of renal care equipment, systems and disposable products. The company also offers Care Coordination services including pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Fresenius Medical Care conducts research to develop and advance its specific adsorber technologies; and develop innovative products and services that incorporate additional elements to improve the quality and safety of treatment options. In FY2022, the company spent EUR229 million on its R&D activities, which as a percentage of revenue, stood at 1.2%, and grew 4% YoY. As of December 31, 2022, the company’s patent portfolio consisted of approximately 10,086 property rights for approximately 1,599 patent families. Its R&D capabilities enabled Fresenius Medical Care to obtain 53 additional patent families in FY2022.